Prediction of efficacy of anticancer agents by in vivo imaging of thymidine phosphorylase

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461889
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Showa Pharmaceutical University
• Principal Investigator: AKIZAWA Hiromichi 昭和薬科大学, 薬学部, 教授 (90311795)
• Co-Investigator(Kenkyū-buntansha): OHKURA Kazue 北海道医療大学, 薬学部, 教授 (60094827) ; KUGE Yuji 北海道大学, アイソトープ総合センター, 教授 (70321958) ; ZHAO Songji 北海道大学, 医学研究科, 特任教授 (80374239)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 核医学 / イメージング / 抗がん剤 / 治療効果予測 / チミジンホスホリラーゼ / 5-フルオロウラシル / カペシタビン / ドキシフルリジン

Outline of Final Research Achievements

Anticancer agents, 5-fluorouracil and its prodrugs, are activated by the action of an enzyme, thymidine phosphorylase (TP). In this study, we evaluated whether the efficacy of the anticancer agents could be predicted by the estimation of TP levels in cancer tissues by our in vivo imaging technique. In vitro studies showed that the higher efficacy of the anticancer agents could be obtained in the cancer cells with the higher level of TP and that factors rather than TP could also affect the efficacy. Therefore, our in vivo imaging technique for estimation of TP levels could be used for predicting the efficacy of the anticancer agents although attention would be required in diagnosis.

Free Research Field

放射薬品化学